Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database

Lugardon, Stéphanie; Roussel, Henri; Sciortino, V.; Montastruc, Jean‐Louis; Lapeyre‐Mestre, Maryse

doi:10.1007/s00228-007-0332-2

Cited by 34 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11][12][13][14][15] The fact that patients who filled their triptan prescriptions only once showed a significant decrease in the rates of physician office visits and diagnostic imaging after their index triptan fill is potentially suggestive of misdiagnosis. If these patients truly suffered from migraines, one would expect their medical services utilization rates to continue increasing on a trajectory similar to or worse than that of patients who frequently switched their triptans The fact that triptans seemed less effective at reducing the utilization of other services and medications among patient who switched triptans frequently is logical if triptan switching is viewed as an indicator of ineffectiveness.…”

Section: Patient Characteristics and Follow-up Time Stratified By Trimentioning

confidence: 99%

See 1 more Smart Citation

Health Care Resource Utilization Following Initiation of a Triptan: A Retrospective Claims Analysis

Messali

Owens²,

Bloudek³

et al. 2014

JMCP

View full text Add to dashboard Cite

Migraine headaches are among the most common neurological disorders in the United States and other Western countries. Eighteen percent of women and 6% of men in the United States above the age of 12 suffer from migraines-roughly 23 million Americans.1 Migraine prevalence is highest among 35 to 45 year olds, Caucasian women, and lower-income households.2 These factors associated with migraine prevalence have been consistently described in research conducted in the United States, Canada, and several European countries. [3][4][5] The direct costs of migraine treatment have been estimated to exceed $1 billion each year. 1,6 About 60% of these direct costs are attributable to physician office visits, and another 30% can be attributed to prescription drug treatment. The remaining 10% consists of inpatient treatment and emergency room visits. As is the case with many chronic diseases, the indirect costs of migraine headaches far outweigh the direct costs. The attributable productivity losses to American employers have been estimated to be roughly $13 billion annually. 1,6 The majority of these productivity losses ($8 billion each year) are the result of migraine-related missed workdays.From a payer's perspective, an important aspect of the value of prescription medications lies in their potential to prevent more costly utilization of health care resources, such as emergency room visits and inpatient hospitalizations, by managing ABSTRACTBACkgRoUnd: 23 million Americans suffer from migraine headaches, incurring more than $1 billion in direct medical costs each year (with another $13 billion in indirect productivity losses). Triptans are the most common treatment of choice for these patients; however, adherence and persistence to triptans are poor. Partly due to poor adherence to therapy, the ability of triptans to reduce the utilization of other medical services and prescription drugs remains unclear.

show abstract

Section: Patient Characteristics and Follow-up Time Stratified By Trimentioning

confidence: 99%

“…9,11 The proportion of patients that fill only 1 triptan prescription without any further refills has ranged from 38% to 56%. 9,10,[12][13][14][15] Triptan brand switching is also a common occurrence. Roughly 15% of triptan users will try a new triptan over 1 year of follow-up.…”

mentioning

confidence: 99%

Health Care Resource Utilization Following Initiation of a Triptan: A Retrospective Claims Analysis

Messali

Owens²,

Bloudek³

et al. 2014

JMCP

View full text Add to dashboard Cite

show abstract

“…Der Zusammenhang zwischen dem Einsatz von Triptane und kardialen Nebenwirkungen wurden in den letzten Jahren kontrovers diskutiert. Ob dabei ein Koronarspasmus die Beschwerden verursacht, ist unklar [5,6,7]. Das Risiko eines Myokardinfarkts bei einer Akutmedikation mit Sumatriptan ist sehr gering und liegt bei 1:1.000.000 [10] …”

Section: Diskussionunclassified

Myokardiale Ischämie als Folge eines übermäßigen Gebrauchs von Kopfschmerzmedikamenten

Kraya

Schlitt

2014

Med Klin Intensivmed Notfmed

View full text Add to dashboard Cite

Myocardial infarction as the most severe clinical manifestation of coronary atherosclerosis is the major cause of death in western countries. Although rupture of an atherosclerotic plaque is generally causal for this event, in recent years differential diagnoses have been discussed to further optimize diagnosis and treatment of myocardial ischemia. The "universal definition of myocardial infarction" defines five subtypes of myocardial infarction: in particular, type 2 myocardial infarction includes other diseases related to myocardial ischemia such as hyper- or hypotension, coronary artery spasms, arrhythmia, etc. Some medications for the acute therapy of migraine like triptans can lead to myocardial infarction.

show abstract

“…This data is made available for academic research in the fields of medicine or pathology. The application of EHR systems is prevalent [1], including well-known systems as the Partners Healthcare Research Patient Data Registry (RPDR) in Boston [2] or the French health system database [3]. One major merit of this type of studies is that these databases collect cases with good demographic diversity.…”

Section: Introductionmentioning

confidence: 99%

Predicting the onset of bullous pemphigoid with co-morbidities: A survey based on a nationwide medical database

Kuo

Yang

et al. 2013

2013 IEEE International Conference on Bioinformatics and Biomedicine

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an acute or chronic autoimmune skin disease. It has been reported that poor conditions of general health and increased mortality rates were observed in BP patients, while pathophysiologic reasons of these phenomena merit further investigation yet. In this paper we tried to investigate the co-morbid associations between bullous pemphigoid and various diseases, using a nationwide population-based medical database, NHIRD. 5,933 adult BP patients of ages >= 18 years were extracted from the NHIRD, accompanied with 17,712 age-and sex-matched control subjects. Thirty-one disorders were selected from the Charlson or Elixhauser index for which we tried to evaluate their respective associations with BP. The results obtained revealed that there existed co-morbid relationships between BP and various illnesses, especially for hemiplegia/paraplegia (odds ratio [OR] 8.71), dementia (OR 8.04), fluid electrolyte disorders (OR 6.6), cerebrovascular disease (OR 5.97), moderate/severe liver disease (OR 5.22), weight loss (OR 4.9), and psychoses (OR 4.64). Furthermore, using the study cohort as input data and the retrospective diagnosis records of the abovementioned co-morbidities occurring within 24 months before onset of BP as features, we employed the algorithm of support vector machine (SVM) to generate the prediction model for onset of BP afterward. Subjects labeled as positive by the prediction model were about 9 times more likely than those as negative to actually develop BP. Accordingly, the prediction model created by SVM was valuable for physicians to screen patients with higher risk of BP.

show abstract

Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database

Cited by 34 publications

References 23 publications

Health Care Resource Utilization Following Initiation of a Triptan: A Retrospective Claims Analysis

Health Care Resource Utilization Following Initiation of a Triptan: A Retrospective Claims Analysis

Myokardiale Ischämie als Folge eines übermäßigen Gebrauchs von Kopfschmerzmedikamenten

Predicting the onset of bullous pemphigoid with co-morbidities: A survey based on a nationwide medical database

Contact Info

Product

Resources

About